Pfizer (PFE) Non-Current Debt (2009 - 2026)

Pfizer (PFE) has 18 years of Non-Current Debt data on file, last reported at $60.6 billion in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $60.6 billion, up 5.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.6 billion (up 5.08% YoY), and the FY2025 annual result was $61.6 billion, up 8.14% from the prior year.
• Non-Current Debt declined to $60.6 billion in Q1 2026 per PFE's latest filing, from $61.6 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $61.6 billion in Q4 2025 and troughed at $31.7 billion in Q2 2023.
• A 5-year average of $51.7 billion and a median of $57.5 billion in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt dropped 11.08% in 2023, then soared 93.37% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $32.9 billion in 2022, then soared by 87.14% to $61.5 billion in 2023, then dropped by 7.37% to $57.0 billion in 2024, then increased by 8.14% to $61.6 billion in 2025, then fell by 1.75% to $60.6 billion in 2026.
• Business Quant data shows PFE's Non-Current Debt at $60.6 billion in Q1 2026, $61.6 billion in Q4 2025, and $57.4 billion in Q3 2025.